REGULATION AND LEGISLATION
BUSINESS AND INVESTMENT
British psychedelics firm Beckley Psytech raises US$3.7 million in Series A funding.
Professor David Nutt joins AWAKN Life Sciences.
Empower Clinics begins search for Dosed Wellness clinic site in Vancouver.
Former Pfizer, Yale drug discovery expert joins Mydecine Innovations’ advisory board.
Numinus Wellness announces the launch of a clinical advisory council.
ATAI is utilising digital tools to improve psychedelic therapies and monitor patients.
Mota Ventures appoints Roger C. Clinton to advisory board of new acquisition, Verrian.
RESEARCH AND SCIENCE
THE PSYCHEDELICS AS MEDICINE REPORT
Medical psychedelics are experiencing a renaissance, pushing forward the frontiers of healthcare innovation.
|PSYCH: The Psychedelics as Medicine Report provides unparalleled insights and intelligence from industry experts and market leaders, helping to guide investors, operators and regulators through this transient phase.|
PSYCH Symposium at Prohibition Partners LIVE brought together world-class speakers, industry giants and pioneering investors, to discuss psychedelics and their potential to disrupt how we treat mental health. Read the highlights.